StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302545% above fair value
$411.29−5.25 (-1.26%)

Close on Nov 16, 2026Market cap $46.76BP/E 73.6Yield –

BeOne Medicines price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BeOne Medicines's price to sales ratio was 7.7× on Nov 11, 2026, against 7.6× a year earlier. Over the last 5 years it ranged from 5.4× to 23.8×, with a median of 7.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.7×+1.0
2025Dec 31, 20256.8×+0.8
2024Dec 31, 20245.9×−2.6
2023Dec 29, 20238.5×−9.8
2022Dec 30, 202218.3×−5.5
2021Dec 31, 202123.8×−64.7
2020Dec 31, 202088.5×+86.2
2019Dec 31, 20192.3×−50.4
2018Dec 31, 201852.7×+32.6
2017Dec 29, 201720.1×−154.0
2016Dec 30, 2016174.1×–

More BeOne Medicines figures

See a number that looks wrong?